<H1>Chapter DOI: 10.1208/aapsj070371<br/>Cited-By Count: 51</H1><table border="1" width="30%"><tr><td>Total References</td><td>118</td></tr><tr><td>Springer references</td><td>4</td></tr><tr><td>Non Springer references</td><td>114</td></tr><tr><td>BibStructured Count</td><td width="10%">118</td></tr><tr><td>BibUnstructured Count</td><td width="10%">0</td></tr><tr><td>DOI already available in SpringerLink</td><td>93</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>3</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>1</td></tr><tr><td>DOI Obtained For Non Springer</td><td>2</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>3</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>0</td></tr><tr><td>Valid DOI Enriched</td><td>1</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1</td><td>BibArticle</td><td>Wang JB, Johnson PS, Persico AM, Hawkins AL, Griffin CA, Uhl GR. Human mu opiate receptor&#8212;cDNA and genomic clones, pharmacologic characterization and chromosomal assignment.<Emphasis Type="Italic">FEBS Lett</Emphasis>. 1994;338:217&#8211;222.</td><td><a href=http://dx.doi.org/10.1016/0014-5793(94)80368-4>10.1016/0014-5793(94)80368-4</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR2</td><td>BibArticle</td><td>Mansson E, Bare L, Yang D. Isolation of a human kappa opioid receptor cDNA from placenta.<Emphasis Type="Italic">Biochem Biophys Res Commun</Emphasis>. 1994;202:1431&#8211;1434.</td><td><a href=http://dx.doi.org/10.1006/bbrc.1994.2091>10.1006/bbrc.1994.2091</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR3</td><td>BibArticle</td><td>Kieffer BL, Befort K, Gavriaux-Ruff C, Hirth CG. The opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterization.<Emphasis Type="Italic">Proc Natl Acad Sci USA</Emphasis>. 1992;89:12048&#8211;12052.</td><td><a href=http://dx.doi.org/10.1073/pnas.89.24.12048>10.1073/pnas.89.24.12048</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR4</td><td>BibArticle</td><td>Peters GR, Gaylor S. Human central nervous system (CNS) effects of a selective kappa opioid agonist [abstract].<Emphasis Type="Italic">Clin Pharmacol Ther.</Emphasis> 1989;45:130.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR5</td><td>BibBook</td><td>Casy AF, Parfitt RT.<Emphasis Type="Italic">Opioid Analgesics</Emphasis> New York and London: Plenum Press; 1986.</td><td><a href=http://dx.doi.org/10.1007/978-1-4899-0585-7>10.1007/978-1-4899-0585-7</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, Author_FamilyName_1, BookTitle, Year</td><td>CrossRef</td></tr><tr><td>CR6</td><td>BibArticle</td><td>Schmidhammer H. Opioid receptor antagonists.<Emphasis Type="Italic">Prog Med Chem.</Emphasis> 1998;35:83&#8211;132.</td><td><a href=http://dx.doi.org/10.1016/S0079-6468(08)70035-3>10.1016/S0079-6468(08)70035-3</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR7</td><td>BibArticle</td><td>Coop A, Rice KC. Role of delta-opioid receptors in biological processes.<Emphasis Type="Italic">Drug News Perspect.</Emphasis> 2000;13:481&#8211;487.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR8</td><td>BibArticle</td><td>Rees DC. Chemical structures and biological activities of nonpeptide selective kappa opioid ligands.<Emphasis Type="Italic">Prog Med Chem.</Emphasis> 1992;29:109&#8211;139.</td><td><a href=http://dx.doi.org/10.1016/S0079-6468(08)70006-7>10.1016/S0079-6468(08)70006-7</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR9</td><td>BibArticle</td><td>Kuzmin AV, Gerrits MAFM, Van Ree JM. Kappa-opioid receptor blockade with nor-binaltorphimine modulates cocaine self-administration in drug-na&#239;ve rats.<Emphasis Type="Italic">Eur J Pharmacol.</Emphasis> 1998;358:197&#8211;202.</td><td><a href=http://dx.doi.org/10.1016/S0014-2999(98)00637-2>10.1016/S0014-2999(98)00637-2</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR10</td><td>BibArticle</td><td>Mague SD, Pliakas AM, Todtenkopf MS, et al. Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats.<Emphasis Type="Italic">J Pharmacol Exp Ther.</Emphasis> 2003;305:323&#8211;330.</td><td><a href=http://dx.doi.org/10.1124/jpet.102.046433>10.1124/jpet.102.046433</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR11</td><td>BibArticle</td><td>Jewett DC, Grace MK, Jones RM, Billington CJ, Portoghese PS, Levine AS. The kappa-opioid antagonist GNTI reduces U50,488-, DAMGO-, and deprivation-induced feeding, but not butorphanol-and neuropeptide-Y-induced feeding in rats.<Emphasis Type="Italic">Brain Res.</Emphasis> 2001;909:75&#8211;80.</td><td><a href=http://dx.doi.org/10.1016/S0006-8993(01)02624-5>10.1016/S0006-8993(01)02624-5</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR12</td><td>BibArticle</td><td>Roth BL, Baner K, Westkaemper R, et al. Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist.<Emphasis Type="Italic">Proc Natl Acad Sci USA</Emphasis>. 2002;99:11934&#8211;11939.</td><td><a href=http://dx.doi.org/10.1073/pnas.182234399>10.1073/pnas.182234399</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR13</td><td>BibArticle</td><td>Schmidhammer H. Opioid receptor antagonists.<Emphasis Type="Italic">Prog Med Chem.</Emphasis> 1998;35:83&#8211;132.</td><td><a href=http://dx.doi.org/10.1016/S0079-6468(08)70035-3>10.1016/S0079-6468(08)70035-3</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR14</td><td>BibArticle</td><td>Bennett MA, Murray TF, Aldrich JV. Identification of arodyn, a novel acetylated dynorphin A-(1&#8211;11) analogue, as a &#954; opioid receptor antagonist.<Emphasis Type="Italic">J Med Chem.</Emphasis> 2002;45:5617&#8211;5619.</td><td><a href=http://dx.doi.org/10.1021/jm025575g>10.1021/jm025575g</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR15</td><td>BibArticle</td><td>Weltrowska G, Lu Y, Lemieux C, Chung NN, Schiller PW. A novel cyclic enkephalin analogue with potent opioid antagonist activity.<Emphasis Type="Italic">Bioorg Med Chem Lett.</Emphasis> 2004;14:4731&#8211;4733.</td><td><a href=http://dx.doi.org/10.1016/j.bmcl.2004.06.077>10.1016/j.bmcl.2004.06.077</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR16</td><td>BibChapter</td><td>Aldrich JV. Analgesics. In: Abraham DJ, ed.<Emphasis Type="Italic">Burger&#8217;s Medicinal Chemistry and Drug Discovery, Volume 6, Nervous System Agents</Emphasis>. 6<Superscript>th</Superscript> ed. New York: John Wiley and Sons; 2003:329&#8211;482.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR17</td><td>BibBook</td><td>Cowan A, Lewis JW.<Emphasis Type="Italic">Buprenorphine: Combatting Drug Abuse with a Unique Opioid</Emphasis>. New York: John Wiley and Sons; 1995.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR18</td><td>BibArticle</td><td>Devi LA. Heterodimerization of G-protein-coupled receptors: pharmacology, signaling, and trafficking.<Emphasis Type="Italic">Trends Pharmacol Sci.</Emphasis> 2001;22:532&#8211;537.</td><td><a href=http://dx.doi.org/10.1016/S0165-6147(00)01799-5>10.1016/S0165-6147(00)01799-5</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR19</td><td>BibArticle</td><td>Rusovici DE, Negus SS, Mello NK, Bidlack JM. &#954;-opioid receptors are differentially labeled by arylacetamides and benzomorphans.<Emphasis Type="Italic">Eur J Pharmacol.</Emphasis> 2004;485:119&#8211;125.</td><td><a href=http://dx.doi.org/10.1016/j.ejphar.2003.11.078>10.1016/j.ejphar.2003.11.078</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR20</td><td>BibArticle</td><td>Zimmerman DM, Leander JD. Selective opioid receptor agonists and antagonists: research tools and potential therapeutic agents.<Emphasis Type="Italic">J Med Chem.</Emphasis> 1990;33:895&#8211;902.</td><td><a href=http://dx.doi.org/10.1021/jm00165a002>10.1021/jm00165a002</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR21</td><td>BibArticle</td><td>Larson DL, Jones RM, Hjorth SA, Schwartz TW, Portoghese PS. Binding of norbinaltorphimine (norBNI) congeners to wild-type and mutant mu and kappa opioid receptors: molecular recognition loci for the pharmacophore and address components of kappa antagonists.<Emphasis Type="Italic">J Med Chem.</Emphasis> 2000;43:1573&#8211;1576.</td><td><a href=http://dx.doi.org/10.1021/jm000059g>10.1021/jm000059g</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR22</td><td>BibArticle</td><td>Jones RM, Hjorth SA, Schwartz TW, Portoghese PS. Mutational evidence for a common &#954; antagonist binding pocket in the wild-type &#954; and mutant &#956;[K303E] opioid receptors.<Emphasis Type="Italic">J Med Chem.</Emphasis> 1998;41:4911&#8211;4914.</td><td><a href=http://dx.doi.org/10.1021/jm9805182>10.1021/jm9805182</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR23</td><td>BibArticle</td><td>Sharma SK, Jones RM, Metzger TG, Ferguson DM, Portoghese PS. Transformation of a &#954;-opioid receptor antagonist to a &#954;-agonist by transfer of a guanidinium group form the 5&#8242;-to the 6&#8242;-position of naltrindole.<Emphasis Type="Italic">J Med Chem.</Emphasis> 2001;44:2073&#8211;2079.</td><td><a href=http://dx.doi.org/10.1021/jm010095v>10.1021/jm010095v</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR24</td><td>BibArticle</td><td>Stevens WC, Jones RM, Subramanian G, Metzger TG, Ferguson DM, Portoghese PS. Potent and selective indolomorphinan antagonists of the kappa-opioid receptor.<Emphasis Type="Italic">J Med Chem.</Emphasis> 2000;43:2759&#8211;2769.</td><td><a href=http://dx.doi.org/10.1021/jm0000665>10.1021/jm0000665</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR25</td><td>BibArticle</td><td>Metzger TG, Paterlini MG, Ferguson DM, Portoghese PS. Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site directed mutagenesis of opioid receptors: exploring the &#8216;address&#8217; recognition locus.<Emphasis Type="Italic">J Med Chem.</Emphasis> 2001;44:857&#8211;862.</td><td><a href=http://dx.doi.org/10.1021/jm000381r>10.1021/jm000381r</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR26</td><td>BibArticle</td><td>Kong H, Raynor K, Yano H, Takeda J, Bell GI, Reisine T. Agonists and antagonists bind to different domanins of the cloned &#954; opioid receptor.<Emphasis Type="Italic">Proc Natl Acad Sci USA</Emphasis>. 1994;91:8042&#8211;8046.</td><td><a href=http://dx.doi.org/10.1073/pnas.91.17.8042>10.1073/pnas.91.17.8042</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR27</td><td>BibArticle</td><td>Hjorth SA, Thirstrup K, Grandy DK, Schwartz TW. Analysis of selective binding epitopes for the &#954;-opioids receptor antagonist nor-binaltorphimine.<Emphasis Type="Italic">Mol Pharmacol.</Emphasis> 1995;47:1089&#8211;1094.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR28</td><td>BibArticle</td><td>Eguchi M. Recent Advances in selective opioid receptor agonists and antagonists.<Emphasis Type="Italic">Med Res Rev.</Emphasis> 2004;24:182&#8211;212.</td><td><a href=http://dx.doi.org/10.1002/med.10059>10.1002/med.10059</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR29</td><td>BibArticle</td><td>Portoghese PS, Lipkowski AW, Takemori AE. Binaltorphimine and nor-binaltorphimine, potent and selective &#954;-opioid receptor antagonists.<Emphasis Type="Italic">Life Sci.</Emphasis> 1987;40:1287&#8211;1292.</td><td><a href=http://dx.doi.org/10.1016/0024-3205(87)90585-6>10.1016/0024-3205(87)90585-6</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR30</td><td>BibArticle</td><td>Butelman ER, Harris TJ, Kreek MJ. The plant-derived hallucinogen, salvinorin A, produces kappa-opioid agonist-like discriminative effects in rhesus monkeys.<Emphasis Type="Italic">Psychopharmacology (Berl)</Emphasis>. 2004;172:220&#8211;224.</td><td><a href=http://dx.doi.org/10.1007/s00213-003-1638-0>10.1007/s00213-003-1638-0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR31</td><td>BibArticle</td><td>Erez M, Takemori AE, Portoghese PS. Narcotic antagonistic potency of bivalent ligands which contain &#946;-naltrexamine. Evidence for bridging between proximal recognition sites.<Emphasis Type="Italic">J Med Chem.</Emphasis> 1982;25:847&#8211;849.</td><td><a href=http://dx.doi.org/10.1021/jm00349a016>10.1021/jm00349a016</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR32</td><td>BibArticle</td><td>Portoghese PS, Takemori AE. TENA, a selective kappa opioid receptor antagonist.<Emphasis Type="Italic">Life Sci.</Emphasis> 1985;36:801&#8211;805.</td><td><a href=http://dx.doi.org/10.1016/0024-3205(85)90202-4>10.1016/0024-3205(85)90202-4</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR33</td><td>BibArticle</td><td>Botros S, Lipkowski AW, Takemori AE, Portoghese PS. Investigation of the structural requirements for the &#954;-selective opioid receptor antagonist, 6&#946;,6&#946;&#8242;-[ethlenebis(oxyethyleneimino)]bis[17-(cyclopropylmethyl)-4,5&#945;-epoxymorphinan-3,14-diol] (TENA).<Emphasis Type="Italic">J Med Chem.</Emphasis> 1986;29:874&#8211;876.</td><td><a href=http://dx.doi.org/10.1021/jm00155a048>10.1021/jm00155a048</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR34</td><td>BibArticle</td><td>Portoghese PS, Ronsisvalle G, Larson DL, Takemori AE. Synthesis and opioid antagonist potencies of naltrexamine bivalent ligands with conformationally restricted spacers.<Emphasis Type="Italic">J Med Chem.</Emphasis> 1986;29:1650&#8211;1653.</td><td><a href=http://dx.doi.org/10.1021/jm00159a014>10.1021/jm00159a014</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR35</td><td>BibArticle</td><td>Portoghese PS, Larson DL, Sayre LM, et al. Opioid agonist and antagonist bivalent ligands. The relationship between spacer length and selectivity at multiple opioid receptors.<Emphasis Type="Italic">J Med Chem.</Emphasis> 1986;29:1855&#8211;1861.</td><td><a href=http://dx.doi.org/10.1021/jm00160a010>10.1021/jm00160a010</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR36</td><td>BibArticle</td><td>Portoghese AS, Lipkowski AW, Takemori AE. Bimorphinans as highly selective, potent &#954; opioid receptor antagonists.<Emphasis Type="Italic">J Med Chem.</Emphasis> 1987;30:238&#8211;239.</td><td><a href=http://dx.doi.org/10.1021/jm00385a002>10.1021/jm00385a002</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR37</td><td>BibArticle</td><td>Takemori AE, Portoghese PS. Selective naltrexone-derived opioid receptor antagonists.<Emphasis Type="Italic">Annu Rev Pharmacol Toxicol.</Emphasis> 1992;32:239&#8211;269.</td><td><a href=http://dx.doi.org/10.1146/annurev.pa.32.040192.001323>10.1146/annurev.pa.32.040192.001323</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR38</td><td>BibArticle</td><td>Portoghese PS. Bivalent ligands and the message-address concept in the design of selective opioid receptor antagonists.<Emphasis Type="Italic">Trends Pharmacol Sci.</Emphasis> 1989;10:230&#8211;235.</td><td><a href=http://dx.doi.org/10.1016/0165-6147(89)90267-8>10.1016/0165-6147(89)90267-8</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR39</td><td>BibArticle</td><td>Schwyzer R. ACTH: a short introductory review.<Emphasis Type="Italic">Ann NY Acad Sci.</Emphasis> 1977;297:3&#8211;26.</td><td><a href=http://dx.doi.org/10.1111/j.1749-6632.1977.tb41843.x>10.1111/j.1749-6632.1977.tb41843.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR40</td><td>BibArticle</td><td>Lin C, Takemori AE, Portoghese PS. Synthesis and &#954;-opioid antagonist selectivity of a norbinaltorphimine congener. Identification of the address moiety reqired for &#954;-antagonist activity.<Emphasis Type="Italic">J Med Chem.</Emphasis> 1993;36:2412&#8211;2415.</td><td><a href=http://dx.doi.org/10.1021/jm00068a020>10.1021/jm00068a020</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR41</td><td>BibArticle</td><td>Thomas JB, Atkinson RN, Vinson A, et al. Identification of (3R)-7-Hydroxy-<Emphasis Type="Italic">N</Emphasis>-((1S)-1-{[(3R, 4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide as a novel potent and selective opioid &#954; receptor antagonist.<Emphasis Type="Italic">J Med Chem.</Emphasis> 2003;46:3127&#8211;3137.</td><td><a href=http://dx.doi.org/10.1021/jm030094y>10.1021/jm030094y</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR42</td><td>BibArticle</td><td>Grundt P, Williams IA, Lewis JW, Husbands SM. Identification of a new scaffold for &#954; opioid receptor antagonism based on the 2-amino-1, 1-dimethyl-7-hydroxytetralin pharmacophore.<Emphasis Type="Italic">J Med Chem.</Emphasis> 2004;47:5069&#8211;5075.</td><td><a href=http://dx.doi.org/10.1021/jm040807s>10.1021/jm040807s</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR43</td><td>BibArticle</td><td>Portoghese PS, Nagase H, Takemori AE. Only one pharmacophore is required for the &#954; opioid antagonist selectivity of norbinaltorphimine.<Emphasis Type="Italic">J Med Chem.</Emphasis> 1988;31:1344&#8211;1347.</td><td><a href=http://dx.doi.org/10.1021/jm00402a015>10.1021/jm00402a015</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR44</td><td>BibArticle</td><td>Portoghese PS, Nagase H, Lipkowski AW, Larson DL, Takemori AE. Binaltorphimine-related bivalent ligands and their &#954; opioid receptor antagonist selectivity.<Emphasis Type="Italic">J Med Chem.</Emphasis> 1988;31:836&#8211;841.</td><td><a href=http://dx.doi.org/10.1021/jm00399a026>10.1021/jm00399a026</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR45</td><td>BibArticle</td><td>Schmidhammer H, Ganglbauer E, Mitterdorfer J, Rollinger JM, Smith CFC. Synthesis and biological evaluation of 14-alkoxymorphinans 14,14&#8242;-dimethoxy analogues of norbinaltorphimine: synthesis and determination of their &#954; opioid antagonist selectivity.<Emphasis Type="Italic">Helv Chim Acta.</Emphasis> 1990;73:1779&#8211;1783.</td><td><a href=http://dx.doi.org/10.1002/hlca.19900730622>10.1002/hlca.19900730622</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR46</td><td>BibArticle</td><td>Schmidhammer H, Smith CFC. A simple and efficient method for the preparation of binaltorphimine and derivatives and determination of their &#954; opioid antagonist selectivity.<Emphasis Type="Italic">Helv Chim Acta</Emphasis>. 1989;72:675&#8211;677.</td><td><a href=http://dx.doi.org/10.1002/hlca.19890720408>10.1002/hlca.19890720408</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR47</td><td>BibArticle</td><td>Portoghese PS, Garzon-Aburbeh A, Nagase H, Lin C, Takemori AE. Role of the spacer in conferring &#954; opioid receptor selectivity to bivalent ligands related to norbinaltorphimine.<Emphasis Type="Italic">J Med Chem.</Emphasis> 1991;34:1292&#8211;1296.</td><td><a href=http://dx.doi.org/10.1021/jm00108a008>10.1021/jm00108a008</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR48</td><td>BibArticle</td><td>Portoghese PS, Lin C, Farouz-Grant R, Takemori AE. Structure-activity relationship of N17&#8242;substituted norbinaltorphimine congeners. Role of the N17&#8242; basic group in the interaction with a putative address subsite on the &#954; opioid receptor.<Emphasis Type="Italic">J Med Chem.</Emphasis> 1994;37:1495&#8211;1500.</td><td><a href=http://dx.doi.org/10.1021/jm00036a015>10.1021/jm00036a015</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR49</td><td>BibArticle</td><td>Thomas JB, Fix SE, Rothman RB, et al., Importance of phenolic address groups in opioid kappa receptor selective antagonists.<Emphasis Type="Italic">J Med Chem.</Emphasis> 2004;47:1070&#8211;1073.</td><td><a href=http://dx.doi.org/10.1021/jm030467v>10.1021/jm030467v</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR50</td><td>BibArticle</td><td>Marki A, Otvos F, Toth G, Hosztafi S, Borsodi A. Tritiated kappa receptor antagonist norbinaltorphimine: synthesis and in vitro binding in three different tissues.<Emphasis Type="Italic">Life Sci.</Emphasis> 2000;66:43&#8211;49.</td><td><a href=http://dx.doi.org/10.1016/S0024-3205(99)00560-3>10.1016/S0024-3205(99)00560-3</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR51</td><td>BibArticle</td><td>Olmsted SL, Takemori AE, Portoghese PS. A remarkable change of opioid receptor selectivity on the attachment of a peptidomimetic &#954; address element to the &#948; antagonist, naltrindole: 5&#8242;-[(N<Superscript>2</Superscript>-alkylamidino) methyl]naltrindole derivatives as a novel class of &#954; opioid receptor antagonists.<Emphasis Type="Italic">J Med Chem.</Emphasis> 1993;36:179&#8211;180.</td><td><a href=http://dx.doi.org/10.1021/jm00053a025>10.1021/jm00053a025</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR52</td><td>BibArticle</td><td>Jones RM, Portoghese PS. 5&#8242;-Guanidinonaltrindole, a highly selective and potent &#954;-opioid receptor antagonist.<Emphasis Type="Italic">Eur J Pharmacol.</Emphasis> 2000;396:49&#8211;52.</td><td><a href=http://dx.doi.org/10.1016/S0014-2999(00)00208-9>10.1016/S0014-2999(00)00208-9</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR53</td><td>BibArticle</td><td>Jales AR, Husbands SM, Lewis JW. Selective &#954;-opioid antagonists related to naltrindole. Effect of side-chain spacer in the 5&#8242;-amidinoalkyl series.<Emphasis Type="Italic">Bioorg Med Chem Lett.</Emphasis> 2000;10:2259&#8211;2261.</td><td><a href=http://dx.doi.org/10.1016/S0960-894X(00)00433-9>10.1016/S0960-894X(00)00433-9</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR54</td><td>BibArticle</td><td>Black SL, Jales AR, Brandt W, Lewis JW, Husbands SM. The role of the side chain in determining relative &#948;- and &#954;-affinity in C5&#8242;-substituted analogues of naltrindole.<Emphasis Type="Italic">J Med Chem.</Emphasis> 2003;46:314&#8211;317.</td><td><a href=http://dx.doi.org/10.1021/jm020997b>10.1021/jm020997b</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR55</td><td>BibArticle</td><td>Black SL, Chauvignac C, Grundt P, et al. Guanidino N-substituted and N,N-disubstituted derivatives of the &#954;-opioid antagonist GNTI.<Emphasis Type="Italic">J Med Chem.</Emphasis> 2003;46:5505&#8211;5511.</td><td><a href=http://dx.doi.org/10.1021/jm0309203>10.1021/jm0309203</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR56</td><td>BibArticle</td><td>Ananthan S, Kezar HS, Saini SK, et al. Synthesis, opioid receptor binding, and functional activity of 5&#8242;-subsitituted 17-cycloprop ylmethylpyrido[2&#8242;,3&#8242;,:6,7]morphinans.<Emphasis Type="Italic">Bioorg Med Chem Lett.</Emphasis> 2003;13:529&#8211;532.</td><td><a href=http://dx.doi.org/10.1016/S0960-894X(02)00934-4>10.1016/S0960-894X(02)00934-4</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR57</td><td>BibArticle</td><td>Thomas JB, Atkinson RN, Rothman RB, et al. Identification of the first<Emphasis Type="Italic">trans</Emphasis>-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine derivative to possess highly potent and selective opioid &#954; receptor antagonist activity.<Emphasis Type="Italic">J Med Chem.</Emphasis> 2001;44:2687&#8211;2690.</td><td><a href=http://dx.doi.org/10.1021/jm015521r>10.1021/jm015521r</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR58</td><td>BibArticle</td><td>Zimmerman DM, Leander JD, Cantrell BE, et al. Structure-activity relationships of<Emphasis Type="Italic">trans</Emphasis>-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine antagonists for &#956;- and &#954;-opioid receptors.<Emphasis Type="Italic">J Med Chem.</Emphasis> 1993;36:2833&#8211;2841.</td><td><a href=http://dx.doi.org/10.1021/jm00072a001>10.1021/jm00072a001</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR59</td><td>BibArticle</td><td>Thomas JB, Fall MJ, Cooper JB, et al. Identification of an opioid &#954; receptor subtype-selective N-substituent for (+)-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine.<Emphasis Type="Italic">J Med Chem.</Emphasis> 1998;41:5188&#8211;5197.</td><td><a href=http://dx.doi.org/10.1021/jm980511k>10.1021/jm980511k</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR60</td><td>BibArticle</td><td>Thomas JB, Atkinson RN, Namdev N, et al. Discovery of an opioid &#954; receptor selective pure antagonist from a library of N-substituted 4&#946;-methyl-5-(3-hydroxyphenyl)morphans.<Emphasis Type="Italic">J Med Chem.</Emphasis> 2002;45:3524&#8211;3530.</td><td><a href=http://dx.doi.org/10.1021/jm020084h>10.1021/jm020084h</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR61</td><td>BibArticle</td><td>Grundt P, Williams IA, Lewis JW, Husbands SM. Identification of a new scaffold for opioid receptor antagonism based on the 2-amino-1, 1-dimethyl-7-hydroxytetralin pharmacophore.<Emphasis Type="Italic">J Med Chem.</Emphasis> 2004;47:5069&#8211;5075.</td><td><a href=http://dx.doi.org/10.1021/jm040807s>10.1021/jm040807s</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR62</td><td>BibArticle</td><td>de Costa BR, Band L, Rothman RB, et al. Synthesis of an affinity ligand (&#8216;UPHIT&#8217;) for in vivo acylation of the &#954;-opioid receptor.<Emphasis Type="Italic">FEBS Lett.</Emphasis> 1989;249:178&#8211;182.</td><td><a href=http://dx.doi.org/10.1016/0014-5793(89)80619-2>10.1016/0014-5793(89)80619-2</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR63</td><td>BibArticle</td><td>de Costa BR, Rothman RB, Bykov V, Jacobson AE, Rice KC. Selective and enantiospecific acylation of &#954; opioid receptors by (1S,2S)-<Emphasis Type="Italic">trans</Emphasis>-2-isothiocyanato-<Emphasis Type="Italic">N</Emphasis>-methyl-<Emphasis Type="Italic">N</Emphasis>-[2-(1-pyrrolidinyl)cyclohecyl]benze neacetamide. Demonstration of &#954; receptor heterogeneity.<Emphasis Type="Italic">J Med Chem.</Emphasis> 1989;32:281&#8211;283.</td><td><a href=http://dx.doi.org/10.1021/jm00122a001>10.1021/jm00122a001</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR64</td><td>BibArticle</td><td>Chang AC, Takemori AE, Portoghese PS. 2-(3,4-dichlorophenyl)-<Emphasis Type="Italic">N</Emphasis>-methyl-<Emphasis Type="Italic">N</Emphasis>-[(1<Emphasis Type="Italic">S</Emphasis>)-1-(3-isothiocyanatophenyl)-2-(1-pyrrolidinyl)ethyl]acet amide: an opioid receptor affinity label that produces selective and long-lasting &#954; antagonism in mice.<Emphasis Type="Italic">J Med Chem.</Emphasis> 1994;37:1547&#8211;1549.</td><td><a href=http://dx.doi.org/10.1021/jm00037a001>10.1021/jm00037a001</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR65</td><td>BibArticle</td><td>Chang AC, Takemori AE, Ojala WH, Gleason WB, Portoghese PS. &#954; opioid receptor selective affinity labels: electrophilic benzeneacetamides as &#954;-selective opioid antagonists.<Emphasis Type="Italic">J Med Chem.</Emphasis> 1994;37:1547&#8211;1549.</td><td><a href=http://dx.doi.org/10.1021/jm00037a001>10.1021/jm00037a001</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR66</td><td>BibArticle</td><td>Chauvignac C, Miller CN, Srivastava SK, Lewis JW, Husbands SM, Taynor JR. Major effect of pyrrolic N-benzylation in norbinaltorphiminie, the selective &#954;-opioid receptor antagonist.<Emphasis Type="Italic">J Med Chem.</Emphasis> 2005;48:1676&#8211;1679.</td><td><a href=http://dx.doi.org/10.1021/jm049172n>10.1021/jm049172n</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR67</td><td>BibArticle</td><td>Negus SS, Mello NK, Linsenmayer DC, Jones RM, Portoghese PS. Kappa opioid antagonist effects of the novel kappa antagonist 5&#8242;-guanidinonaltrindole (GNTI) in an assay of schedule-controlled behavior in rhesus monkeys.<Emphasis Type="Italic">Psychopharmacology (Berlin)</Emphasis>. 2002;163:412&#8211;419.</td><td><a href=http://dx.doi.org/10.1007/s00213-002-1038-x>10.1007/s00213-002-1038-x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR68</td><td>BibArticle</td><td>Bertalmio AJ, Woods JH. Differentiation between<Emphasis Type="Italic">mu</Emphasis> and<Emphasis Type="Italic">kappa</Emphasis> receptor-mediated effects in opioid drug discrimination: apparent pA<Subscript>2</Subscript> analysis.<Emphasis Type="Italic">J Pharmacol Exp Ther.</Emphasis> 1987;243:591&#8211;597.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR69</td><td>BibArticle</td><td>Negus SS, Butelman ER, Chang KJ, DeCosta B, Winger G, Woods JH. Behavioral effects of the systemically active<Emphasis Type="Italic">delta</Emphasis> opioid agonist BW373U86 in rhesus monkeys.<Emphasis Type="Italic">J Pharmacol Exp Ther.</Emphasis> 1994;270:1025&#8211;1034.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR70</td><td>BibArticle</td><td>Carroll I, Thomas JB, Dykstra LA, et al. Pharmacological properties of JDTic: a novel &#954;-opioid receptor antagonist.<Emphasis Type="Italic">Eur J Pharmacol.</Emphasis> 2004;501:111&#8211;119.</td><td><a href=http://dx.doi.org/10.1016/j.ejphar.2004.08.028>10.1016/j.ejphar.2004.08.028</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR71</td><td>BibArticle</td><td>Butelman ER, Negus SS, Ai Y, deCosta BR, Woods JH. Kappa opioid antagonist effects of systemically administered norbinaltorphimine in a thermal antinociception assay in rhesus monkeys.<Emphasis Type="Italic">J Pharmacol Exp Ther.</Emphasis> 1993;267:1269&#8211;1276.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR72</td><td>BibArticle</td><td>Endoh T, Matsuura H, Tanaka C, Nagase H. Nor-binaltorphimine: a potent and selective kappa-opioid receptor antagonist with long-lasting activity in vivo.<Emphasis Type="Italic">Arch Int Pharmacodyn Ther.</Emphasis> 1992;316:30&#8211;42.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR73</td><td>BibArticle</td><td>Broadbear JH, Negus SS, Butelman ER, de Costa BR, Woods JH. Differential effects of systemically administered nor-binaltorphimine (nor-BNI) on kappa-opioid agonists in the mouse writhing assay.<Emphasis Type="Italic">Psychopharmacology (Berlin)</Emphasis>. 1994;115:311&#8211;319.</td><td><a href=http://dx.doi.org/10.1007/BF02245071>10.1007/BF02245071</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR74</td><td>BibArticle</td><td>Ko MCH, Lee H, Song MS, et al. Activation of &#954;-opioid receptors inhibits pruritus evoked by subcutaneous or intrathecal administration of morphine in monkeys.<Emphasis Type="Italic">J Pharmacol Exp Ther.</Emphasis> 2003;305:173&#8211;179.</td><td><a href=http://dx.doi.org/10.1124/jpet.102.044909>10.1124/jpet.102.044909</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR75</td><td>BibArticle</td><td>Jones DNC, Holtzman SG. Long term kappa opioid receptor blockade following nor-binaltorphimine.<Emphasis Type="Italic">Eur J Pharmacol.</Emphasis> 1992;215:345&#8211;348.</td><td><a href=http://dx.doi.org/10.1016/0014-2999(92)90055-9>10.1016/0014-2999(92)90055-9</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR76</td><td>BibArticle</td><td>Horan P, Taylor J, Yamamura HI, Porreca F. Extremely long-lasting antagonistic actions of nor-binaltorphimine (nor-BNI) in the mouse tail-flick test.<Emphasis Type="Italic">J Pharmacol Exp Ther.</Emphasis> 1992;260:1237&#8211;1243.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR77</td><td>BibArticle</td><td>Ko MCH, Johnson MD, Butelman ER, Willmont KJ, Mosberg HI, Woods JH. Intracisternal nor-binaltorphimine distinguishes central and peripheral kappa-opioid antinociception in rhesus monkeys.<Emphasis Type="Italic">J Pharmacol Exp Ther.</Emphasis> 1999;291:1113&#8211;1120.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR78</td><td>BibArticle</td><td>Jewett DC, Woods JH. Nor-binaltorphimine: a very, very long acting kappa opioid antagonist in pigeons.<Emphasis Type="Italic">Behav Pharmacol.</Emphasis> 1995;6:815&#8211;820.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1097/00008877-199512000-00007>10.1097/00008877-199512000-00007</a></td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, ArticleTitle, VolumeID, Year</td><td>CrossRef</td></tr><tr><td>CR79</td><td>BibArticle</td><td>Takemori AE, Ho BY, Naeseth JS, Portoghese PS. Norbinaltorphimine, a highly selective kappa-opioid antagonist in analgesic and receptor binding assays.<Emphasis Type="Italic">J Pharmacol Exp Ther.</Emphasis> 1988;246:255&#8211;258.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR80</td><td>BibArticle</td><td>Takemori AE, Schwartz MM, Portoghese PS. Suppression by norbinaltorphimine of<Emphasis Type="Italic">kappa</Emphasis> opioid-mediated diuresis in rats.<Emphasis Type="Italic">J Pharmacol Exp Ther.</Emphasis> 1988;247:971&#8211;974.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR81</td><td>BibArticle</td><td>Ko MCH, Willmont KJ, Lee H, Flory GS, Woods JH. Ultra-long antagonism of kappa opioid agonist-induced diuresis by intracisternal nor-binaltorphimine in monkeys.<Emphasis Type="Italic">Brain Res.</Emphasis> 2003;982:38&#8211;44.</td><td><a href=http://dx.doi.org/10.1016/S0006-8993(03)02938-X>10.1016/S0006-8993(03)02938-X</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR82</td><td>BibArticle</td><td>Carlezon WA Jr, Thome J, Olson VG, et al. Regulation of cocaine reward by CREB.<Emphasis Type="Italic">Science</Emphasis>. 1998;282:2272&#8211;2275.</td><td><a href=http://dx.doi.org/10.1126/science.282.5397.2272>10.1126/science.282.5397.2272</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR83</td><td>BibArticle</td><td>Pliakas AM, Carlson RR, Neve RL, Konradi C, Nestler EJ, Carlexon WA. Altered responsiveness to cocaine and increased immobility in the forced swim test associated with elevated cAMP response element-binding protein expression in nucleus accum bens.<Emphasis Type="Italic">J Neurosci.</Emphasis> 2001;21:7397&#8211;7403.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR84</td><td>BibArticle</td><td>McLaughlin JP, Marton-Popovici M, Chavkin C. &#954; opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses.<Emphasis Type="Italic">J Neurosci.</Emphasis> 2003;23:5674&#8211;5683.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR85</td><td>BibArticle</td><td>Berrocoso E, Rojas-Corrales MO, Mico JA. Non-selective opioid receptor antagonism of the antidepressant-like effect of venlafaxine in the forced swimming test in mice.<Emphasis Type="Italic">Neurosci Lett.</Emphasis> 2004;363:25&#8211;28.</td><td><a href=http://dx.doi.org/10.1016/j.neulet.2004.03.041>10.1016/j.neulet.2004.03.041</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR86</td><td>BibArticle</td><td>Newton SS, Thome J, Wallace TL, et al. Inhibition of cAMP response element-binding protein or dynorphin in the nucleus accum bens produces an antidepressant-like effect.<Emphasis Type="Italic">J Neurosci.</Emphasis> 2002;22:10883&#8211;10890.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR87</td><td>BibArticle</td><td>Shirayama Y, Ishida H, Iwata M, Hazama G, Kawahara R, Duman RS. Stress increases dynorphin immunoreactivity in limbic brain regions and dynorphin antagonism produces antidepressant-like effects.<Emphasis Type="Italic">J Neurochem.</Emphasis> 2004;90:1258&#8211;1268.</td><td><a href=http://dx.doi.org/10.1111/j.1471-4159.2004.02589.x>10.1111/j.1471-4159.2004.02589.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR88</td><td>BibArticle</td><td>Kamei J, Nagase H. Norbinaltorphimine, a selective &#954; opioid receptor antagonist, induces an itch-associated response in mice.<Emphasis Type="Italic">Eur J Pharmacol.</Emphasis> 2001;418:141&#8211;145.</td><td><a href=http://dx.doi.org/10.1016/S0014-2999(01)00941-4>10.1016/S0014-2999(01)00941-4</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR89</td><td>BibArticle</td><td>Cowan A, Inan S, Kehner GB. GNTI, a kappa receptor antagonist, causes compulsive scratching in mice.<Emphasis Type="Italic">The Pharmacologist.</Emphasis> 2002;44:A51.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR90</td><td>BibArticle</td><td>Togashi Y, Umeuchi H, Okano K, et al. Antipruritic activity of the &#954;-opioid receptor agonist, TRK-820.<Emphasis Type="Italic">Eur J Pharmacol.</Emphasis> 2002;435:259&#8211;264.</td><td><a href=http://dx.doi.org/10.1016/S0014-2999(01)01588-6>10.1016/S0014-2999(01)01588-6</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR91</td><td>BibArticle</td><td>Ko MCH, Lee H, Song MS, et al. Activation of &#954;-opioid receptors inhibits pruritus evoked by subcutaneous of intrathecal administration of morphine in monkeys.<Emphasis Type="Italic">J Pharmacol Exp Ther.</Emphasis> 2003;305:173&#8211;179.</td><td><a href=http://dx.doi.org/10.1124/jpet.102.044909>10.1124/jpet.102.044909</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR92</td><td>BibArticle</td><td>Umeuchi H, Togashi Y, Honda T, et al. Involvement of central &#956;-opioid system in the scratching behavior in mice, and the suppression of it by the activation of &#954;-opioid system.<Emphasis Type="Italic">Eur J Pharmacol.</Emphasis> 2003;477:29&#8211;35.</td><td><a href=http://dx.doi.org/10.1016/j.ejphar.2003.08.007>10.1016/j.ejphar.2003.08.007</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR93</td><td>BibArticle</td><td>Levine AS, Grace M, Portoghese PS, Billington CJ. The effect of selective opioid antagonists on butorphanol-induced feeding.<Emphasis Type="Italic">Brain Res.</Emphasis> 1994;637:242&#8211;248.</td><td><a href=http://dx.doi.org/10.1016/0006-8993(94)91239-4>10.1016/0006-8993(94)91239-4</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR94</td><td>BibArticle</td><td>Cole JL, Berman N, Bodnar RJ. Evaluation of chronic opioid receptor antagonist effects upon weight and intake measures in lean and obese zucker rats.<Emphasis Type="Italic">Peptides</Emphasis>. 1997;18:1201&#8211;1207.</td><td><a href=http://dx.doi.org/10.1016/S0196-9781(97)00074-0>10.1016/S0196-9781(97)00074-0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR95</td><td>BibArticle</td><td>Bodnar RJ, Glass MJ, Ragnauth A, Cooper ML. General, &#956; and &#954; opioid antagonists in the nucleus accum bens alter food intake under deprivation, glucoprivic and palatable conditions.<Emphasis Type="Italic">Brain Res.</Emphasis> 1995;700:205&#8211;212.</td><td><a href=http://dx.doi.org/10.1016/0006-8993(95)00957-R>10.1016/0006-8993(95)00957-R</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR96</td><td>BibArticle</td><td>Leventhal L, Kirkham TC, Cole JL, Bodnar RJ. Selective actions of central &#956; and &#954; opioid antagonists upon sucrose intake in sham-fed rats.<Emphasis Type="Italic">Brain Res.</Emphasis> 1995;685:205&#8211;210.</td><td><a href=http://dx.doi.org/10.1016/0006-8993(95)00385-4>10.1016/0006-8993(95)00385-4</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR97</td><td>BibArticle</td><td>Khaimova E, Kandov Y, Israel Y, Cataldo G, Hadjimarkou MM, Bodnar RJ. Opioid receptor subtype antagonists differentially alter GABA agonist-induced feeding elicited from either the nucleus accumbens shell or ventral tegmental area regions in rats.<Emphasis Type="Italic">Brain Res.</Emphasis> 2004;1026:284&#8211;294.</td><td><a href=http://dx.doi.org/10.1016/j.brainres.2004.08.032>10.1016/j.brainres.2004.08.032</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR98</td><td>BibArticle</td><td>Kotz CM, Grace MK, Billington CJ, Levine AS. The effect of norbinaltorphimine, &#946;-funaltrexamine and naltrindole on NPY-induced feeding.<Emphasis Type="Italic">Brain Res.</Emphasis> 1993;631:325&#8211;328.</td><td><a href=http://dx.doi.org/10.1016/0006-8993(93)91552-4>10.1016/0006-8993(93)91552-4</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR99</td><td>BibArticle</td><td>Calcagnetti DJ, Calcagnetti RL, Fanselow MS. Centrally administered opioid antagonists, nor-binaltorphimine, 16-methyl cyprenorphine, and Mr2266, suppress intake of a sweet solution.<Emphasis Type="Italic">Pharmacol Biochem Behav.</Emphasis> 1990;35:69&#8211;73.</td><td><a href=http://dx.doi.org/10.1016/0091-3057(90)90206-W>10.1016/0091-3057(90)90206-W</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR100</td><td>BibArticle</td><td>Spanagel R, Shippenberg TS. Modulation of morphine-induced sensitization by endogenous &#954; opioid systems in the rat.<Emphasis Type="Italic">Neurosci Lett.</Emphasis> 1993;153:232&#8211;236.</td><td><a href=http://dx.doi.org/10.1016/0304-3940(93)90329-J>10.1016/0304-3940(93)90329-J</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR101</td><td>BibArticle</td><td>Williams KL, Ko MHC, Rice KC, Woods JH. Effect of opioid receptor antagonists on hypothalamic-pituitary-adrenal activity in rhesus monkeys.<Emphasis Type="Italic">Psychoneuroendocrinology</Emphasis>. 2003;28:513&#8211;528.</td><td><a href=http://dx.doi.org/10.1016/S0306-4530(02)00037-9>10.1016/S0306-4530(02)00037-9</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR102</td><td>BibArticle</td><td>Narita M, Kishimoto Y, Ise Y, Yajima Y, Misawa K, Suzuki T. Direct evidence for the involvement of the mesolimbic &#954;-opioid system in the morphine-induced rewarding effect under an inflammatory pain-like state.<Emphasis Type="Italic">Neuropsychopharmacology</Emphasis>. 2005;30:111&#8211;118.</td><td><a href=http://dx.doi.org/10.1038/sj.npp.1300527>10.1038/sj.npp.1300527</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR103</td><td>BibArticle</td><td>Joynes RL, Grau JW. Instrumental learning within the spinal cord: III. Prior exposure to noncontingent shock induces a behavioral deficit that is blocked by an opioid antagonist.<Emphasis Type="Italic">Neurobiol Learn Mem.</Emphasis> 2004;82:35&#8211;51.</td><td><a href=http://dx.doi.org/10.1016/j.nlm.2004.04.001>10.1016/j.nlm.2004.04.001</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR104</td><td>BibArticle</td><td>Cheng HY, Laviolette SR, van der Kooy D, Penninger JM. DREAM ablation selectively alters THC place aversion and analgesia but leaves intact the motivational and analgesic effects of morphine.<Emphasis Type="Italic">Eur J Neurosci.</Emphasis> 2004;19:3033&#8211;3041.</td><td><a href=http://dx.doi.org/10.1111/j.0953-816X.2004.03435.x>10.1111/j.0953-816X.2004.03435.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR105</td><td>BibArticle</td><td>Mizoguchi H, Leitermann RJ, Narita M, Nagase H, Suzuki T, Tseng LF. Region-dependent G-protein activation by &#954;-opioid receptor agonists in the mouse brain.<Emphasis Type="Italic">Neurosci Lett.</Emphasis> 2004;356:145&#8211;147.</td><td><a href=http://dx.doi.org/10.1016/j.neulet.2003.09.034>10.1016/j.neulet.2003.09.034</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR106</td><td>BibArticle</td><td>Fan L, Tien L, Tanaka S, et al. Enhanced binding of norbinaltorphimine to &#954;-opioid receptors in rats dependent on butorphanol.<Emphasis Type="Italic">J Neurosci Res.</Emphasis> 2003;72:781&#8211;789.</td><td><a href=http://dx.doi.org/10.1002/jnr.10578>10.1002/jnr.10578</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR107</td><td>BibArticle</td><td>Cosentino M, Marino F, DePonti F, et al. Tonic modulation of neurotransmitter release in the guinea-pig myenteric plexus: effect of &#956; and &#954; opioid receptor blockade and of chronic sympathetic denervation.<Emphasis Type="Italic">Neurosci Lett.</Emphasis> 1995;194:185&#8211;188.</td><td><a href=http://dx.doi.org/10.1016/0304-3940(95)11757-N>10.1016/0304-3940(95)11757-N</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR108</td><td>BibArticle</td><td>Ossipov MH, Kovelowski CJ, Wheeler-Aceto H, et al. Opioid antagonists and antisera to endogenous opioids increase the nociceptive response to formalin: demonstration of an opioid<Emphasis Type="Italic">kappa</Emphasis> and<Emphasis Type="Italic">delta</Emphasis> inhibitory tone.<Emphasis Type="Italic">J Pharmacol Exp Ther.</Emphasis> 1996;277:784&#8211;788.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR109</td><td>BibArticle</td><td>Obara I, Mika J, Schafer MK-H, Przewlocka B. Antagonists of the &#954;-opioid receptor enhance allodynia in rats and mice after sciatic nerve ligation.<Emphasis Type="Italic">Br J Pharmacol.</Emphasis> 2003;140:538&#8211;546.</td><td><a href=http://dx.doi.org/10.1038/sj.bjp.0705427>10.1038/sj.bjp.0705427</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR110</td><td>BibArticle</td><td>Baker AK, Meert TF. Functional effects of systemically administered agonists and antagonists of &#956;, &#948;, and &#954; opioid receptor subtypes on body temperature in mice.<Emphasis Type="Italic">J Pharmacol Exp Ther.</Emphasis> 2002;302:1253&#8211;1264.</td><td><a href=http://dx.doi.org/10.1124/jpet.102.037655>10.1124/jpet.102.037655</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR111</td><td>BibArticle</td><td>Tortella FC, Echevarria E, Lipkowski AW, Takemori AE, Portoghese PS, Holaday JW. Selective kappa antagonist properties of nor-binaltrophimine in the rat seizure model.<Emphasis Type="Italic">Life Sci.</Emphasis> 1989;44:661&#8211;665.</td><td><a href=http://dx.doi.org/10.1016/0024-3205(89)90470-0>10.1016/0024-3205(89)90470-0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR112</td><td>BibArticle</td><td>Manzanares J, Lookingland KJ, LaVigne SD, Moore KE. Activation of tuberohypophysial dopamine neurons following intracerebroventricular administration of the selective kappa opioid receptor antagonist nor-binaltorphimine.<Emphasis Type="Italic">Life Sci.</Emphasis> 1991;48:1143&#8211;1149.</td><td><a href=http://dx.doi.org/10.1016/0024-3205(91)90451-G>10.1016/0024-3205(91)90451-G</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR113</td><td>BibArticle</td><td>McIntosh M, Kane K, Parratt J. Effects of selective opioid receptor agonists and antagonists during myocardial ischaemia.<Emphasis Type="Italic">Eur J Pharmacol.</Emphasis> 1992;210:37&#8211;44.</td><td><a href=http://dx.doi.org/10.1016/0014-2999(92)90649-O>10.1016/0014-2999(92)90649-O</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR114</td><td>BibArticle</td><td>Llobel F, Laorden ML. Effects of &#956;-, &#948;-, and &#954;-opioid antagonists in atrial preparations from failing human hearts.<Emphasis Type="Italic">Gen Pharmacol.</Emphasis> 1997;28:371&#8211;374.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR115</td><td>BibArticle</td><td>Cao Z, Liu L, VanWinkle DM. Activation of &#948;- and &#954;-opioid receptors by opioid peptides protects cardiomyocytes via K<Subscript>ATP</Subscript> channels.<Emphasis Type="Italic">Am J Physiol Heart Circ Physiol.</Emphasis> 2003;285:H1032-H1039.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR116</td><td>BibArticle</td><td>Carey GJ, Bergman J. Enadoline discrimination in squirrel monkeys: effects of opioid agonists and antagonists.<Emphasis Type="Italic">J Pharmacol Exp Ther.</Emphasis> 2001;297:215&#8211;223.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR117</td><td>BibArticle</td><td>Jewett DC, Woods JH. Nor-binaltorphimine: an ultra-long acting kappa-opioid antagonist in pigeons.<Emphasis Type="Italic">Behav Pharmacol.</Emphasis> 1995;6:815&#8211;820.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1097/00008877-199512000-00007>10.1097/00008877-199512000-00007</a></td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Author_FamilyName_2, VolumeID, Year</td><td>CrossRef</td></tr><tr><td>CR118</td><td>BibArticle</td><td>Picker MJ, Mathewson C, Allen RM. Opioids and rate of positively reinforced behavior: III. Antagonism by the long-lasting kappa antagonist norbinaltorphimine.<Emphasis Type="Italic">Behav Pharmacol.</Emphasis> 1996;7:495&#8211;504.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></table>